Sign up to save your podcasts
Or
Share Clinician’s Update on Omega-3s in ASCVD Risk Reduction
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Clinician’s Update on Omega-3s in ASCVD Risk Reduction
CME credits: 0.25
Valid until: 30-09-2022
Claim your CME credit at https://reachmd.com/programs/cme/clinicians-update-omega-3s-ascvd-risk-reduction/12718/
More than 15 professional societies now recommend the use of icosapent ethyl to treat atherosclerotic cardiovascular disease (ASCVD), but clinical questions about the use of omega-3 fatty acids remain. Dr. Leslie Cho and Dr. Erin Michos discuss the role of DHA and EPA and whether all omega-3 fatty acids are the same. But what about EPA plasma levels, incidence of atrial fibrillation, and differences between the STRENGTH and REDUCE-IT trials? Tune in to get these answers and more!
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.25
Valid until: 30-09-2022
Claim your CME credit at https://reachmd.com/programs/cme/clinicians-update-omega-3s-ascvd-risk-reduction/12718/
More than 15 professional societies now recommend the use of icosapent ethyl to treat atherosclerotic cardiovascular disease (ASCVD), but clinical questions about the use of omega-3 fatty acids remain. Dr. Leslie Cho and Dr. Erin Michos discuss the role of DHA and EPA and whether all omega-3 fatty acids are the same. But what about EPA plasma levels, incidence of atrial fibrillation, and differences between the STRENGTH and REDUCE-IT trials? Tune in to get these answers and more!